Table 3_The benefit and risk of adding PD-1/PD-L1 inhibitors plus anti-VEGF drugs to trans

Four randomized controlled trials (CARES-005, EMERALD-1, LEAP-012, and TALENTACE) involving 1,431 patients were pooled to evaluate a combination therapy for unresectable, non-metastatic hepatocellular carcinoma. Tonggang Zhou published this analysis on figshare in May 2026 under a CC-BY-4.0 license. The analysis compares survival and adverse event outcomes between standard treatment and the combination therapy.

Use Cases

• Compare progression-free survival (PFS) and overall survival (OS) outcomes between treatment groups based on hazard ratios.
• Analyze tumor response rates (ORR) using RECIST and mRECIST criteria.
• Evaluate the incidence and severity of adverse events (AEs), including treatment-emergent and immune-related events.
• Perform subgroup analyses to assess treatment benefit consistency across patient demographics.
• Assess treatment discontinuation reasons (due to adverse events or disease progression).

Strengths

• Data is derived from four randomized controlled trials, a rigorous study design.
• Includes 1,431 patient records, providing a substantial sample size.
• Analyzes multiple endpoints including survival, tumor response, and adverse events.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The file format is DOC, which may require conversion for structured data analysis.

Provenance

Source

figshare

Collection Method

Systematic search of six databases and pooled analysis of identified RCTs.

Freshness

Last updated 2026-05-25 13:05:29; freshness should be verified.